Davunetide (AL-108) PSP Trial

Trial Synopsis

Davunetide (also known as AL-108, NAP, or NAPvasop) was a neuroprotective peptide developed by Allon Therapeutics Inc. that was evaluated in a Phase 2 clinical trial for Progressive Supranuclear Palsy (PSP). The trial failed to meet its primary endpoint, providing important lessons about neuroprotective strategies in tauopathies^{1ClinicalTrials.gov: AL-108 in PSP (NCT00490781)Open reference2Allon Therapeutics Pipeline InformationOpen reference}.

Overview

flowchart TD
    PSP["PSP"] -->|"associated with"| Alzheimer["Alzheimer"]
    PSP["PSP"] -->|"associated with"| Als["Als"]
    PSP["PSP"] -->|"associated with"| Alzheimer_s_disease["Alzheimer's disease"]
    PSP["PSP"] -->|"expressed in"| neurons["neurons"]
    PSP["PSP"] -->|"downregulates"| SV2A["SV2A"]
    PSP["PSP"] -->|"targets"| tauopathy["tauopathy"]
    PSP["PSP"] -->|"participates in"| unfolded_protein_response["unfolded protein response"]
    PSP["PSP"] -->|"regulates"| STX6["STX6"]
    PSP["PSP"] -->|"associated with"| frontotemporal_dementia["frontotemporal dementia"]
    PSP["PSP"] -->|"participates in"| oxidative_stress_response["oxidative stress response"]
    PSP["PSP"] -->|"associated with"| Parkinson_s_disease["Parkinson's disease"]
    PSP["PSP"] -->|"regulates"| Parkinson_s_disease["Parkinson's disease"]
    PSP["PSP"] -->|"associated with"| tauopathy["tauopathy"]
    PSP["PSP"] -->|"biomarker for"| Ms["Ms"]
    style PSP fill:#4fc3f7,stroke:#333,color:#000

Davunetide (also known as AL-108, NAP, or NAPvasop) was a neuroprotective peptide developed by Allon Therapeutics Inc. It was evaluated in a Phase 2 clinical trial for Progressive Supranuclear Palsy (PSP). The trial failed to meet its primary endpoint, providing important lessons about neuroprotective strategies in tauopathies.^{1ClinicalTrials.gov: AL-108 in PSP (NCT00490781)Open reference2Allon Therapeutics Pipeline InformationOpen reference}

Trial Details (Expanded)

Key Trial Endpoints

Mechanism of Action

Davunetide was a synthetic peptide derived from the neuroprotective protein Activity-Dependent Neuroprotective Protein (ADNP). The drug was designed to:

1. Microtubule stabilization - The peptide helped maintain cytoskeletal integrity by stabilizing microtubules, which are disrupted in tauopathies

2. Neuroprotection - Protected neurons from various insults including oxidative stress and excitotoxicity

3. Anti-inflammatory effects - Reduced neuroinflammation associated with neurodegeneration

The peptide was administered intranasally, which was designed to bypass the blood-brain barrier and deliver the drug directly to the brain.^{2Allon Therapeutics Pipeline InformationOpen reference}

Rationale for PSP

PSP is characterized by tau pathology affecting the brainstem and subcortical structures. The neuroprotective mechanism of davunetide was considered relevant because:

• Tau dysfunction leads to microtubule destabilization

• Neuronal loss in PSP involves oxidative stress and excitotoxicity

• Neuroprotective approaches could potentially slow disease progression

Trial Results

The Phase 2 trial failed to demonstrate efficacy:

• Primary endpoint: No significant improvement in PSP Rating Scale (PSPRS) scores vs. placebo

• Secondary endpoints: No significant benefits in cognitive or motor measures

• Safety profile: Generally well-tolerated with mild-to-moderate adverse events

The negative result was considered a significant setback for neuroprotective approaches in PSP.^{1ClinicalTrials.gov: AL-108 in PSP (NCT00490781)Open reference}

Failure Analysis

Statistical Considerations

The trial’s failure to meet its primary endpoint can be analyzed from multiple perspectives:

Sensitivity Analyses

Post-hoc analyses may include:

1. Per-protocol analysis: Excluding protocol deviations

2. Completer analysis: Only participants completing study

3. Dose-response: Exploring dose subgroups

4. Baseline imbalance: Adjusting for covariates

Regulatory Considerations

The FDA Fast Track designation reflected the high unmet need in PSP:

• Unmet need: No approved disease-modifying therapies

• Serious condition: Progressive neurodegenerative disease

• Trial design: Traditional endpoint approach

• Outcome: Insufficient efficacy for approval

Impact on the Field

The davunetide failure had several impacts:

1. Investment caution: Reduced VC funding for neuroprotection

2. Mechanism skepticism: Questioning single-target approaches

3. Regulatory scrutiny: Higher bar for PSP trials

4. Research emphasis: Shift to combination approaches

Potential Reasons for Failure

1. Insufficient target engagement - The intranasal delivery may not have achieved adequate drug concentrations in the brain

2. Mechanism limitations - Microtubule stabilization alone may be insufficient to modify disease progression in established PSP

3. Timing - Patients with established neurodegeneration may be beyond the point where neuroprotection can provide meaningful benefit

4. Biomarker gaps - Without clear biomarkers for target engagement, it was difficult to confirm the drug was hitting its target

Lessons Learned

• Neuroprotective strategies may need to be initiated very early in disease course

• Combination approaches targeting multiple pathways may be more effective than single mechanisms

• Biomarker-driven patient selection could improve trial sensitivity

• Direct measurement of target engagement is critical for future trials

• Intranasal delivery may have limited CNS penetration for neuroprotective peptides

Clinical Development History

Timeline of Davunetide Development

Competitive Landscape

The neuroprotective therapy field in tauopathies includes:

Company Background

Allon Therapeutics was a biopharmaceutical company focused on developing neuroprotective therapies:

• Founded: 2001 (Vancouver, Canada)

• Focus: CNS neurodegenerative diseases

• Funding: ~$100M raised over company lifetime

• Employees: ~50 at peak

• Outcome: Ceased operations 2013 after trial failure

Intranasal Delivery Considerations

Rationale for Intranasal Administration

The intranasal route was chosen for several reasons^{3NAP (Davunetide) in neurodegenerative disease models2007 · J Neural Transm Suppl · PMID 17606689Open reference}:

Challenges with Intranasal Delivery

Despite the rationale, challenges included:

1. Variable absorption: Individual differences in nasal physiology

2. Limited volume: Maximum dose constrained by nasal capacity

3. Mucociliary clearance: Reduces residence time

4. First-pass metabolism: Partial degradation in nasal cavity

5. Particle size: Optimal droplet size required

Alternative Delivery Methods Considered

Other delivery approaches that could be explored:

Therapeutic Implications

Why Neuroprotection Fails in Established Disease

The davunetide trial failure reflects broader challenges:

Future Directions for Neuroprotection

Based on lessons learned:

1. Early intervention: Focus on prodromal or pre-symptomatic stages

2. Biomarker-confirmed enrollment: Require biomarker evidence of pathology

3. Combination therapy: Target multiple pathways

4. Novel delivery: Improve CNS penetration

5. Genetic stratification: Select patients most likely to respond

Ongoing Neuroprotective Strategies

Similar neuroprotective strategies still being explored in PSP include:

• Microtubule stabilizers - Other compounds targeting microtubule function

• Anti-tau antibodies - Immunotherapy approaches (e.g., gosuranemab, tilavonemab, semorinemab)

• Tau ASOs - Antisense oligonucleotides targeting tau (e.g., BIIB080/MAPTRx, NIO752, IONIS-MAPTRx)(see NCT05348786)

• Tau aggregation inhibitors - Drugs preventing tau misfolding

• Neurotrophic factors - BDNF mimetics and NGF modulators

Regulatory History

Development Timeline

FDA Interaction

The FDA granted Fast Track designation to davunetide for PSP in 2010, acknowledging the high unmet need in this indication. Despite this designation, the negative Phase 2 results led to program discontinuation.

Mechanism Deep Dive

ADNP and Navops

Davunetide is derived from ADNP (Activity-Dependent Neuroprotective Protein), a naturally occurring neuroprotective protein:

• ADNP function: Regulates neuronal survival, plasticity, and function

• ADNP activity: Protects against various neurotoxic insults

• Davunetide (NAP): 8-amino acid peptide representing the active domain

Molecular Targets

1. Microtubule stabilization:

   • Binds to microtubule-associated proteins (MAPs)

   • Prevents tau-induced microtubule dysfunction

   • Maintains axonal transport

2. Anti-apoptotic effects:

   • Modulates Bcl-2 family proteins

   • Reduces caspase activation

   • Preserves mitochondrial integrity

3. Anti-inflammatory activity:

   • Reduces pro-inflammatory cytokine release

   • Modulates microglia activation

   • May reduce neuroinflammation in tauopathies

Target Engagement and Biomarkers

Challenges in Demonstrating Target Engagement

The davunetide trial highlights a critical challenge in neuroprotective drug development—the inability to directly measure target engagement in the brain:

Biomarker Approaches for Future Trials

Future neuroprotective trials could incorporate:

Monitoring Neuronal Health

In the absence of direct target engagement measures, alternative approaches include:

1. Neurofilament light chain (NfL): Marker of neuronal injury

2. Volumetric MRI: Regional brain atrophy rates

3. FDG-PET: Metabolic changes

4. CSF total tau: Disease progression marker

Summary and Legacy

Trial Outcome Summary

The davunetide PSP Phase 2 trial represents an illustrative case study in CNS drug development:

The negative result was unexpected given positive preclinical data, highlighting the challenge of translating animal model findings to human neurodegenerative disease.

Contributing Factors to Failure

Multiple factors contributed to the trial failure:

1. Insufficient brain exposure: Intranasal delivery may not have achieved therapeutic concentrations

2. Wrong disease stage: Established PSP may be beyond rescue by neuroprotection

3. Mechanism limitations: Single-target approach may be inadequate

4. Biomarker gaps: No way to confirm target engagement

Lasting Legacy

Despite the negative outcome, the program contributed lasting value:

1. Validated intranasal delivery: Demonstrated feasibility in large trial

2. Established clinical infrastructure: Built PSP trial network

3. Generated natural history data: Informing future trials

4. Taught important lessons: Guiding subsequent development

Industry Context

The trial occurred during a period of intense investment in neuroprotective therapies:

• 2000s: Peak of neuroprotective drug development

• Funding environment: Significant venture capital interest

• Company landscape: Multiple biotech focused on neuroprotection

• Outcome: Many failures led to field consolidation

Future Therapy Directions

Current approaches building on lessons learned:

Comparison with Other Approaches

Neuroprotective Mechanisms in Clinical Development

Preclinical Data Summary

Animal Model Evidence

The preclinical program included multiple animal model studies:

Translation Challenges

The translation from animal models to human trials faced challenges:

Species Differences

Key differences between preclinical species and humans:

1. Microtubule dynamics: Different in humans vs. rodents

2. ADNP expression: Species-specific patterns

3. BBB characteristics: Variations in permeability

4. Disease models: Induced vs. progressive pathology

5. Immunogenicity: Peptide clearance differences

Biomarker Correlations

The trial incorporated exploratory biomarker analyses:

Imaging Correlations

Neuroimaging was integrated to understand treatment effects:

The imaging findings confirmed disease progression despite treatment, suggesting inadequate biological activity of davunetide at the achieved brain concentrations.

Impact on Neuroprotective Drug Development

Industry Implications

The davunetide failure affected the broader neuroprotective drug development landscape:

Academic Research Implications

The failure also influenced academic research directions:

1. Mechanism focus: Shift from single to combination targets

2. Biomarker emphasis: Integration of biomarkers in trials

3. Early intervention: Focus on prodromal disease

4. Delivery innovation: BBB-penetrating approaches

Future Outlook

Lessons for Future Trials

1. Early intervention: Neuroprotection may only be effective in prodromal or early disease stages

2. Biomarker enrichment: Patient selection based on biomarker evidence of target engagement

3. Combination therapy: Multi-target approaches may be necessary

4. Delivery optimization: New formulations to improve CNS penetration

Alternative Delivery Methods

Future neuroprotective approaches may explore:

• Intravenous delivery with BBB-penetrating peptides

• Intraventricular infusion for direct CNS delivery

• Gene therapy for continuous neuroprotective protein expression

• Exosome-mediated delivery for targeted CNS delivery

Clinical and Regulatory Insights

Trial Design Implications

The Phase 2 trial design reflected the challenges inherent in neuroprotective drug development for chronic neurodegenerative diseases:

Statistical Power

The trial was designed to detect a clinically meaningful difference:

• Assumed effect size: 3-4 points on PSPRS

• Variability assumptions: Based on natural history

• Power: 80% to detect difference at p<0.05

• Result: Not achieved - insufficient power or no effect

Post-Trial Analyses

Comprehensive analyses after trial completion:

1. Subgroup analyses: By disease severity, duration

2. Biomarker correlations: Exploratory biomarker associations

3. Pharmacogenetics: Genetic predictors of response

4. Long-term follow-up: Open-label extension

Economic Considerations

The trial represented significant investment:

Cross-Links to NeuroWiki

• Alzheimer’s Disease

• Parkinson’s Disease

External Links

• PubMed

• KEGG Pathways

Conclusion and Final Assessment

Clinical Significance

The davunetide Phase 2 trial in PSP, while ultimately unsuccessful, represents an important chapter in neurodegeneration drug development:

Path Forward

The failure of davunetide and similar neuroprotective approaches points toward a new paradigm:

1. Target validation before large trials

2. Biomarker incorporation for patient selection

3. Combination approaches rather than single mechanisms

4. Prevention trials rather than treatment of established disease

The neuroscience community continues to build on these lessons, with ongoing programs applying the insights gained from this and similar trials.

Final Takeaways and Summary

The Phase 2 clinical trial of davunetide (AL-108) in PSP represents an important case study in neuroprotective drug development for tauopathies. The trial failure provides critical lessons for the field:

Key Learnings:

• Single-target neuroprotection is insufficient for established PSP

• Intranasal delivery may not achieve adequate CNS concentrations

• Disease modification requires very early intervention

• Biomarkers are essential for target engagement confirmation

Future Directions:

• Focus on prodromal/preventive interventions

• Develop biomarker-driven patient stratification

• Pursue multi-target combination approaches

• Improve CNS delivery methods

The legacy of the davunetide program continues to inform neuroprotective drug development for PSP and related tauopathies.